These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 33796113)

  • 41. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
    ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
    Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NMOSD and MOGAD: an evolving disease spectrum.
    Uzawa A; Oertel FC; Mori M; Paul F; Kuwabara S
    Nat Rev Neurol; 2024 Oct; 20(10):602-619. PubMed ID: 39271964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
    Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
    J Neurol; 2024 Jul; 271(7):4412-4422. PubMed ID: 38668889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood parameters in pediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Peternell A; Lechner C; Breu M; Preisel M; Schimmel M; Eisenkölbl A; Zobel J; Wendel EM; Reindl M; Rostásy K; Baumann M
    Eur J Paediatr Neurol; 2024 May; 50():86-95. PubMed ID: 38705015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
    Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C
    J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
    Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
    Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C
    J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
    Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
    Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.